Juan Liang
About Juan Liang
Juan Liang is a Senior Biomarker Scientist at BeiGene with a PhD from Tsinghua University and over 7 years of experience at BeiGene.
Company
Juan Liang is currently employed at BeiGene, where she serves as a Senior Biomarker Scientist. She joined BeiGene in 2016 as a Senior Research Investigator before being promoted to her current position in 2018. BeiGene is a global biotechnology company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer.
Title
Juan Liang holds the title of Senior Biomarker Scientist at BeiGene. In this role, she focuses on the identification and validation of biomarkers that can aid in cancer diagnosis, prognosis, and therapy response. This position necessitates significant expertise in biomarker discovery and development.
Education and Expertise
Juan Liang has an extensive academic background. She earned a Doctor of Philosophy (PhD) from Tsinghua University, one of China's leading universities, where she studied from 2005 to 2011. Prior to that, she completed her bachelor's degree at the same institution between 2001 and 2005. Her advanced studies have provided her with a solid foundation in biomedical sciences, a crucial requirement for her work in biomarker research.
Professional Background
Juan Liang has a diverse professional background. She spent five years as a Postdoctoral Fellow at Oregon Health & Science University (OHSU) from 2011 to 2016. In 2016, she joined BeiGene as a Senior Research Investigator, a role she held for one year before being promoted to Senior Biomarker Scientist in 2018. She has accumulated over 7 years of experience at BeiGene, specializing in the development of biomarkers for cancer treatment.
Experience at BeiGene
Juan Liang has been working at BeiGene since 2016. Initially, she was employed as a Senior Research Investigator and was later promoted to Senior Biomarker Scientist in 2018. Throughout her career at BeiGene, she has focused extensively on biomarker research and development, contributing significantly to the company's oncology initiatives. Her role involves the identification and validation of biomarkers to improve cancer diagnostics, prognostics, and treatment responses.